Akero Therapeutics, Inc. AKRO
We take great care to ensure that the data presented and summarized in this overview for Akero Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKRO
View all-
Rtw Investments, LP New York, NY6.86MShares$293 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$258 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$239 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$224 Million5.21% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$185 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.7MShares$158 Million0.0% of portfolio
-
State Street Corp Boston, MA2.34MShares$99.8 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.84MShares$78.6 Million0.02% of portfolio
-
Alkeon Capital Management LLC New York, NY1.76MShares$75.2 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA1.56MShares$66.6 Million0.0% of portfolio
Latest Institutional Activity in AKRO
Top Purchases
Top Sells
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Transactions at AKRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-4.58%
|
$1,050,000
$35.23 P/Share
|
|
Apr 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.9%
|
$225,000
$36.56 P/Share
|
|
Apr 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+3.43%
|
$131,250
$21.1 P/Share
|
|
Mar 27
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
50,000
+4.0%
|
$2,150,000
$43.55 P/Share
|
|
Mar 26
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
58,691
+4.86%
|
$2,523,713
$43.01 P/Share
|
|
Mar 25
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
91,309
+7.72%
|
$4,017,596
$44.75 P/Share
|
|
Mar 17
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.83%
|
$440,000
$44.88 P/Share
|
|
Mar 17
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.69%
|
$210,000
$21.1 P/Share
|
|
Mar 12
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,738
-0.26%
|
$76,472
$44.88 P/Share
|
|
Mar 12
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
614
-0.64%
|
$27,016
$44.88 P/Share
|
|
Mar 12
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
607
-0.3%
|
$26,708
$44.88 P/Share
|
|
Mar 12
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
676
-1.08%
|
$29,744
$44.88 P/Share
|
|
Mar 12
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
516
-0.3%
|
$22,704
$44.88 P/Share
|
|
Mar 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.19%
|
$1,260,000
$42.03 P/Share
|
|
Mar 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.47%
|
$550,000
$44.65 P/Share
|
|
Mar 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.4%
|
$262,500
$21.1 P/Share
|
|
Mar 04
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
50,000
-10.32%
|
$2,200,000
$44.62 P/Share
|
|
Mar 03
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
1,000
-2.9%
|
$48,000
$48.09 P/Share
|
|
Mar 03
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+2.82%
|
$19,000
$19.87 P/Share
|
|
Feb 18
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.77%
|
$500,000
$50.21 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 238K shares |
|---|---|
| Exercise of conversion of derivative security | 1.01M shares |
| Open market or private purchase | 400K shares |
| Open market or private sale | 1.19M shares |
|---|---|
| Bona fide gift | 28.1K shares |